Study number

Case fatality rate or mortality rate

References

1

Overall 64% (11/17)

[64]

2

Overall 54% (501/929)

- 96% of patients died with disseminated mucormycosis.

- 85% with gastrointestinal mucormycosis, and

- 76% with pulmonary mucormycosis

- 46% with sinus infection

[39]

3

32% (19/60)

- 36% of patients were immunocompromised.

- 22% were immunocompetent.

- 18% of patients treated with Liposomal Amphotericin B (L-AMB).

[40]

4

11.5% (61/531)

- 47.8% of patients with haematologic malignancies, and

- 36.4% with bone marrow transplantation.

[65]

5

65% (20/31)

[66]

6

53% (10/19)

- 75% of patient receiving antifungal treatment alone, and

- 14% receiving a combined treatment (antifungal and surgery).

[67]

7

47% (108/230)

- 76% of patients with Hematopoietic stem cell transplantation (HSCT)

- 58% with disseminated mucormycosis

- 56% with pulmonary mucormycosis

- 52% with haematologic malignancies

- 44% with diabetes.

[30]

8

44% (44/101)

- 25% of patient with rhinocerebral mucormycosis,

- 79% with disseminated mucormycosis

- 48% with pulmonary mucormycosis, and

- 22% with cutaneous mucormycosis.

[31]